Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease
详细信息 查看全文
- 作者：Emmanuel J. Favaloro ; emmanuel.favaloro@health.nsw.gov.au" class="auth_mail" title="E-mail the corresponding author ; Soma Mohammed
- 关键词：CLA ; Chemiluminescent assay ; ELISA ; enzyme linked immunosorbent assay ; FVIII ; C ; FVIII coagulant ; GPIb ; glycoprotein Ib ; HMW ; high molecular weight (VWF) ; LIA ; latex-particle immuno-assay ; VWD ; von Willebrand disease ; VWF ; von Willebrand factor ; VWF Ac ; VWF INNOVANCE activity (assay) ; VWF ; Ag ; VWF antigen ; VWF ; CB ; VWF collagen binding (assay) ; VWF ; RCo ; VWF ristocetin cofactor (assay)
- 刊名：Thrombosis Research
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：141
- 期：Complete
- 页码：202-211
- 全文大小：1100 K
文摘
- •
von Willebrand disease (VWD) is the most common bleeding disorder and arises from deficiency and/or defects of von Willebrand factor (VWF).
- •
Laboratory diagnosis and typing of VWD requires a wide range of tests, including VWF antigen and various activities.
- •
We assessed the ACL AcuStar™, and an associated HemosIL AcuStar three test panel, for ability to identify and provisionally type VWD.
- •
This test system was compared to previously evaluated and validated test systems and the study employed a large total sample test set (n= 535).
- •
This study is the first independent evaluation of the HemosIL VWF:CB, and the comprehensive three chemiluminescent-based VWF test panel set.